J. Wang Et Al. , "Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study," Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Louisiana, United States Of America, 2022
Wang, J. Et Al. 2022. Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study. Annual Meeting of the American-Association-for-Cancer-Research (AACR) , (Louisiana, United States Of America).
Wang, J., Ma, Z., Huang, D., Fan, Y., Yu, X., Hu, S., ... Wang, Z.(2022). Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study . Annual Meeting of the American-Association-for-Cancer-Research (AACR), Louisiana, United States Of America
Wang, Jie Et Al. "Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study," Annual Meeting of the American-Association-for-Cancer-Research (AACR), Louisiana, United States Of America, 2022
Wang, Jie Et Al. "Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study." Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Louisiana, United States Of America, 2022
Wang, J. Et Al. (2022) . "Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study." Annual Meeting of the American-Association-for-Cancer-Research (AACR) , Louisiana, United States Of America.
@conferencepaper{conferencepaper, author={Jie Wang Et Al. }, title={Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): Sub-analysis from phase 3 RATIONALE-303 randomized clinical study}, congress name={Annual Meeting of the American-Association-for-Cancer-Research (AACR)}, city={Louisiana}, country={United States Of America}, year={2022}}